Elanco Animal Health (NYSE:ELAN) Insider Buys $99,938.85 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Rajeev Modi bought 4,911 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Elanco Animal Health Stock Down 0.8%

ELAN stock traded down $0.16 on Tuesday, hitting $19.78. 7,919,678 shares of the company’s stock were exchanged, compared to its average volume of 5,317,265. Elanco Animal Health Incorporated has a 12-month low of $12.40 and a 12-month high of $27.72. The firm has a 50 day moving average price of $23.23 and a two-hundred day moving average price of $23.33. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The stock has a market cap of $9.88 billion, a P/E ratio of -39.55, a price-to-earnings-growth ratio of 2.14 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same period in the previous year, the business earned $0.37 EPS. The firm’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 1.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in shares of Elanco Animal Health by 38.0% during the first quarter. Bank of America Corp DE now owns 3,358,215 shares of the company’s stock valued at $80,362,000 after acquiring an additional 924,032 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Elanco Animal Health by 4.9% during the first quarter. Janus Henderson Group PLC now owns 226,000 shares of the company’s stock valued at $5,413,000 after acquiring an additional 10,600 shares during the last quarter. Arkadios Wealth Advisors raised its holdings in shares of Elanco Animal Health by 20.0% during the first quarter. Arkadios Wealth Advisors now owns 63,457 shares of the company’s stock valued at $1,519,000 after acquiring an additional 10,589 shares during the last quarter. Amundi raised its holdings in shares of Elanco Animal Health by 101.9% during the first quarter. Amundi now owns 98,313 shares of the company’s stock valued at $2,353,000 after acquiring an additional 49,608 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Elanco Animal Health by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 9,415 shares of the company’s stock valued at $225,000 after acquiring an additional 3,215 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. KeyCorp boosted their price target on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Morgan Stanley boosted their price target on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Leerink Partners boosted their price target on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Finally, Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.